Description of the trials
| Trial name | Total sample size | Special population | Permit prior statin* | Ave age | Run-in period | Median years F/U |
| Placebo moderate | ||||||
| 4D, A2024 | 1255 | DM II, ESRD | Y, -HS | 66 | Placebo | 4.0 |
| 4S, S20-S4025 | 4444 | MI or angina | Y, -HS | 59 | Placebo | 5.4 |
| AFCAPS, L20-L4026 | 6605 | Healthy adults | N | 58 | Placebo+diet | 5.2 |
| ALERT, F40-F8027 | 2094 | Renal trans | N | 50 | None | 5.4 |
| ASCOT, A1028 29 | 10 810 | HTN+CVD risk | N | 63 | Not statin | 3.3 |
| ASPEN, A1030 | 2410 | DM II | Y, -HS | 61 | Placebo | 4.0 |
| AURORA, R1031 | 2767 | ESRD | N | 64 | Placebo | 3.2 |
| CARDS, A1032 33 | 2838 | DM II | Y, -HS | 62 | Placebo | 4.0 |
| CARE, P4034 | 4159 | MI | Y, -HS | 59 | Placebo | 5.0 |
| CORONA, R1035 | 5011 | ESRD | Y, -HS | 73 | Placebo | 2.7 |
| GISSI-HF, R1036 | 4574 | CHF | Y, -HS | 68 | None | 3.9 |
| HOPE-3, R1037 | 6349 | Healthy, CVD risk | Y, -HS | 66 | Statin | 5.6 |
| LIPID, P4038 | 9014 | MI or angina | Y | 62† | Placebo+diet | 6.0 (mean) |
| LIPS, F8039 | 1640 | Coronary percutaneous intervention | Y | 60 | None | 3.9 |
| MRC/BHF (HPS), S4040 41 | 20 536 | CHD/CHD risk | N | 64 | Placebo, then statin | 5 (mean) |
| PROSPER, P4042 | 5804 | Elderly, CHD risk | Y | 75 | Placebo | 3.2 (mean) |
| WOSCOPS, P4043 44 | 6604 | Healthy males | Y | 55 | None | 4.9 (mean) |
| Placebo-High | ||||||
| JUPITER, R2046 | 17 802 | Healthy adults | N | 66 | Placebo | 1.9‡ |
| SPARCL, A8045 | 4731 | CVA/TIA | Y | 63 | None | 4.9 |
| TRACE, A4047 | 3002 | RA | N, -HS | 61 | None | 2.5 |
| Moderate to high | ||||||
| A to Z, S40-S80 vs 0-S2011 | 4497 | Acute coronary syndrome | N | 61 | None | 1.98 |
| PROVE-IT, A80 vs P4013 | 4162 | Acute coronary syndrome | Y, if <80 mg | 58 | None | 2.0 (mean) |
| SEARCH, S80 vs S2010 | 12 064 | MI | Y | 64 | Statin+placebo | 6.7 |
| TNT, A80 versus A1012 | 10 001 | CHD | Y | 61 | Statin | 4.9 |
*Y=yes, N=no and -HS=statin hypersensitivity exclusion.
†Median.
‡Trial was designed for 2 years of follow-up but met study end points and terminated the blinded portion of the study earlier.